Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety & Tolerability, and PK of INS1007 Administered Once Daily for 24 Weeks in Subjects With Non-CF Bronchiectasis - The Willow Study

Next Previous
Trial Profile

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety & Tolerability, and PK of INS1007 Administered Once Daily for 24 Weeks in Subjects With Non-CF Bronchiectasis - The Willow Study

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brensocatib (Primary)
  • Indications Bronchiectasis
  • Focus Therapeutic Use
  • Acronyms Willow
  • Sponsors Insmed

    • Most Recent Events

    • 13 Sep 2023 Results assessing baseline characteristics and treatment outcomes by eosinophilic endotype (eosinophil count ) among WILLOW patients presented at the 33rd Annual Congress of the European Respiratory Society
    • 13 Sep 2023 Results assessing whether Brensocatib 25mg significantly increases sputum SLPI levels indicating downstream effects of protease inhibition on host defence, presented at the 33rd Annual Congress of the European Respiratory Society
    • 24 May 2023 Results assessing whether brensocatib would reduce airway AZU1 levels in patients with bronchiectasis presented at the 119th International Conference of the American Thoracic Society
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top